UK Modern Slavery Act Statement 2025
Amicus Therapeutics UK Limited ("Amicus UK") makes this statement (pursuant to section 54 Part 6 of the U.K. Modern Slavery Act of 2015) describing the steps Amicus UK has taken to mitigate the risk of slavery and human trafficking in its supply chain and businesses. This statement covers Amicus UK's financial year from January 1, 2025, to December 31, 2025.
Our Business
Amicus UK is a subsidiary of Amicus Therapeutics Inc. (Nasdaq: FOLD) and part of the Amicus Group of companies ("Amicus Group") which is a global, patient-dedicated group of companies focused on discovering, developing, and delivering medicines for people living with rare genetic and metabolic disorders.
Amicus UK's supply chain generally comprises (i) suppliers of direct materials (active ingredients, manufacturing, packaging materials and logistics providers) and (ii) suppliers of indirect services (professional services, facilities, sales, and marketing agencies and clinical research organisations). In our office spaces, we engage suppliers to provide office cleaning services.
From our internal risk assessment, we consider the risk of modern slavery and human trafficking in our operations to be low. Nevertheless, we undertake a series of measures to raise awareness and enhance our programme. Should any concerns be identified, we will take targeted remedial and/or preventative action, as appropriate.
This statement is made by and relates to Amicus UK only.
Policies
Our Code of Conduct is the guide to our culture and values. The Code was updated in 2025 and includes our mission focused behaviours which are: innovation, mission, performance, and integrity. The Code is a critical document that explains our broad values and our commitment to a culture of compliance.
The Code of Conduct and Compliance Programme, along with other policies and standard operating procedures, contain multiple provisions that help to combat modern slavery, forced labour, and human trafficking, specifically:
Code of Conduct Section 3.2
- Commits all Amicus Group companies, including Amicus UK, to never using child or forced labour and establishes that should we become aware of suppliers who violate these principles, we will terminate our relationship with them as their association with us is a reflection on our ethics.
- Affirms that upholding human rights is a direct reflection of our commitment to ethical business practices and that Amicus Group is committed to providing all associates with fair and competitive wages in exchange for high performance conducted with high integrity.
- Sets out that we comply with the wage and labour laws of every country in which we operate and will never use child or forced labour in our operations.
Compliance Programme
- Amicus Group's compliance and ethics programme requires that Amicus UK employees receive training on and must adhere to the Code of Conduct (in 2025 additional language was added concerning the prevention of fraud). The Code of Conduct and the written policies and training programmes that support it, are designed to create a culture of ethics and integrity and to facilitate compliance with the laws of all jurisdictions in which Amicus UK operates.
Reporting
- All Amicus Group and Amicus UK employees are advised to speak up if they have any concerns relating to a breach of our Code of Conduct or any applicable laws. Amicus Group's Compliance programme provides relevant training and multiple channels of communication through which Amicus UK employees, contractors, and business partners can report concerns regarding potential misconduct (including directly or through Amicus' Hotline ("Speak Up!") or website).
- Anonymous reports can be made through our Global Hotline. All Amicus Group, including Amicus UK toll-free hotline numbers are easily accessible on the front page of our intranet. Employees and contractors may also make a report electronically through the Hotline's web-portal. Amicus Group and Amicus UK take violations of our Code and the law very seriously. All allegations of wrongdoing will be promptly and thoroughly investigated without fear of retaliation. Any retaliation will be treated as a breach of the Code of Conduct.
Global Anti Bribery and Corruption Policy
- Amicus' Group and Amicus UK prohibits every form of Bribery and corrupt conduct, and does not solicit, accept, offer, promise, or pay bribes — whether directly or through a third party. This is vital to maintaining the trust of our employees, of the patients we serve, and of the customers and partners with whom we work.
Written Agreements
- Amicus UK contractually require the individuals and companies we engage to fully comply with all applicable local laws and regulations in all activities they may undertake to provide services to us, depending on the nature of the services we include the right to audit and visit any site to review compliance by our vendors and suppliers.
Due Diligence Processes
Amicus UK Employees
- All employees who work for Amicus UK are background checked, having their identity, qualifications and previous work history verified as a condition of employment. We abide by the requirements of the UK Border Agency and verify employees' right to live and work in the UK. Regular audits are made of employees who have only a temporary right to remain. Amicus UK ensures that all employees are paid at minimum in accordance with National Minimum Wage legislation. Employees are encouraged to provide feedback through regular staff surveys. The results of these surveys influence our business activities and decision making.
Ongoing and Future Efforts
In 2025, a Modern Slavery eLearning module was undertaken by all employees across the Amicus group. The training was designed to strengthen awareness of modern slavery risks, help employees recognise potential indicators of exploitation, and ensure they understand the appropriate channels for raising concerns.
Explicit contractual language is being included in company agreements with third parties depending on the risk assessed at pre-contract stage.
Embedding these expectations into our contractual framework strengthens our ability to assess third parties and supports our ongoing efforts to enhance the controls we have in place to detect and mitigate the risk of modern slavery and human trafficking.
During 2025, as part of our work concerning direct "product suppliers", we have continued to apply mechanisms and processes, implemented in 2022, to confirm their adherence to anti-slavery measures in their businesses.
An internal Modern Slavery Committee, chaired by a senior leader appointed as the organisation's Modern Slavery Representative, was established in November 2022. The Committee operates under delegated authority from the Amicus UK Board of Directors to oversee, guide, and further develop our Modern Slavery Programme.
Throughout 2025, the Committee met quarterly to monitor progress against the commitments made in the 2024 Modern Slavery Statement, to continuously assess the effectiveness of the programme, and to review relevant media reports and external developments. This enables the Committee to identify emerging risks and determine whether any elements of the programme require enhancement or amendment.
Due diligence questions relating to modern slavery continue to be incorporated into our supplier onboarding processes, proportionate to the assessed level of risk. This approach helps us identify potential concerns early and ensures that our suppliers meet our ethical and compliance expectations.
There have been no reports received in relation to modern slavery or human trafficking through the Amicus' Global Hotline ("Speak Up!"), as at the date of the Statement.
Amicus UK continues to assess the slavery and human trafficking risks and over the course of 2026 we will continue to raise awareness in the organisation about these risks.
This Statement has been approved by the Amicus UK board of directors as of 25 June 2026.
Steve Green
Director
Amicus Therapeutics UK Limited